type of report	**Current report**
number	56/2014
company	Pharmena Spółka Akcyjna

Information on the progress in clinical trials over innovative anti-atherosclerosis medicinal product 1-MNA

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and the communication on the progress in clinical trials over innovative anti-atherosclerosis medicinal product 1-MNA (published in current report no. 41/2014 of 4th August 2014), the Management of Board PHARMENA S.A. informs that as of 29th September 2014, 23 patients were included to phase II clinical trials over anti-atherosclerosis medicinal product 1-MNA, seven of which have already concluded the trials.

Due to strict criteria of patents' inclusion into the trials (among others those concerning lipid profile disorders and the prohibition to use other dyslipidemia treatments), the number of patients excluded from the trials is higher than previously expected. Pursuant to the recommendation of Montreal Heart Institute (i.e. the institution carrying out the trials), the Issuer has decided to modify the protocol of the trial concerning the criteria of inclusion. HDL –c cholesterol will not be taken into account as an inclusion criterion, however its levels will still be monitored during the trials. Initially, the criterion related to HDL-c cholesterol was incorporated in the trials' protocol on cognitive motivation. The implemented modification will not influence the process of project's commercialisation, but it will certainly streamline the rate of patients' recruitment.

Now, the Company awaits for the consent of Health Canada (the institution that is supervising the phase II clinical trials over anti-atherosclerosis medicinal product 1-MNA) to implement the modification in the clinical trials' protocol. In a separate current report, the company will inform about receiving of the consent to implement the modification in the clinical trials' protocol.

Having taken into account the current number of patients included in the trials and the planned modification of trials' protocol concerning HDL cholesterol, the scheduled conclusion of trials should take place in Q2 2015. The extension of the time needed to conclude the trials will not significantly affect the estimated costs of phase II clinical trial over the 1-MNA anti-atherosclerosis medicinal product.

The aim of the phase II clinical trial over the 1-MNA anti-atherosclerosis medicinal product will consist in establishing the effective dose of the medicinal product and confirming the lack of side effects in humans in the tested doses. Montreal Heart Institute serves as the supervisory institution.

Montreal Heart Institute is a leading research centre in Canada, specialising in cardiology, and one of the largest institutes of this type in the world. It is a world-renowned Institute, that has introduced many innovatory solutions nationally and worldwide. For more information, see www.icm-mhi.org.

Phase II clinical trial ("Proof of Concept") are financed from funds raised in issue of series D shares.

This information is made public due to the fact that conducting phase II clinical trial is necessary for commercialisation of 1-MNA anti-atherosclerotic medicinal product project, while potential revenues on the medicinal product commercialisation may have very significant impact on financial results and market valuation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska - Vice President of the Board